Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy.Novo Nordisk on Tuesday asked the Food and Drug Administration to prevent compounding pharmacies from making unapproved and often cheaper versions of its popular weight loss injection Wegovy and diabetes treatment Ozempic, arguing that the medications are too complex for those manufacturers to make safely. The FDA still has to make a final decision on whether to bar compounded versions of semaglutide, the active ingredient in Ozempic an ...

Novo Nordisk (NVO) announced positive top-line data from a late-stage cardiovascular outcomes study that evaluated its oral semaglutide compared with placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE).The enrolled patient population comprised those with type 2 diabetes (T2D) and established cardiovascular disease and/or chronic kidney disease (CKD). Novo Nordisk further stated that 49% of the enrolled patients received SGLT2i, the standard-of-care ther ...

Novo Nordisk (NVO) shares have lost 4.5% in the past month compared with the industry's decline of 1.5%. The company has also underperformed in the sector and the S&P 500 in the past month, as seen in the chart below. The stock is currently trading below both its 50 and 200-day moving averages. NVO Stock Underperforms the Industry, Sector & the S&P 500 Image Source: Zacks Investment Research Novo Nordisk's stock price primarily dipped after U.S. Senator Bernie Sanders criticized the company for charging hig ...

Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has issued a positive opinion, recommending the approval of Alhemo (concizumab) as the first once-daily subcutaneous prophylactic treatment for patients aged 12 years or older living with haemophilia A or B with inhibitors. Novo Nordisk's Alhemo is a monoclonal antibody that blocks the TFPI, a protein that prevents blood clotting. By inhibiting TFPI, Alhemo promotes thrombin productio ...

JR Research is an opportunistic investor. He was recognized by TipRanks as a Top Analyst. He was also recognized by Seeking Alpha as a "Top Analyst To Follow" for Technology, Software, and Internet, as well as for Growth and GARP. He identifies attractive risk/reward opportunities supported by robust price action to potentially generate alpha well above the S&P 500. He has also demonstrated outperformance with his picks. He focuses on identifying growth investing opportunities that present the most attracti ...

文章核心观点 - 公司宣布了SOUL心血管结局试验的主要结果 [1][2] - 该试验比较了口服塞马格鲁肽与安慰剂作为标准护理的辅助治疗,在预防主要不良心血管事件(MACE)方面取得了统计学显著和优于安慰剂的降低 [2] - 口服塞马格鲁肽在安全性和耐受性方面与之前的试验结果一致 [2] 试验概况 - 该试验是一项多中心、国际、随机、双盲、平行组、安慰剂对照的3期心血管结局试验,共入组9,650名患者 [3] - 试验旨在评估口服塞马格鲁肽相比安慰剂在2型糖尿病合并既往心血管疾病和/或慢性肾脏疾病患者中降低MACE风险的疗效 [4] 产品信息 - 口服塞马格鲁肽每日一次,有3 mg、7 mg和14 mg三种剂量,商品名为Rybelsus [5] - 在欧盟,新的1.5 mg、4 mg和9 mg剂量的Rybelsus已获批,与原有剂量生物等效 [5] 公司概况 - 诺和诺德是一家领先的全球医疗保健公司,总部位于丹麦,成立于1923年 [6] - 公司的宗旨是通过开创性的科学突破、扩大药品可及性以及预防和治愈疾病来战胜严重的慢性疾病 [6] - 公司在80个国家雇佣约69,000名员工,产品销往约170个国家,B股在纳斯达克哥本哈根上市,ADR在纽约证券交易所上市 [6]

文章核心观点 - 欧洲药品管理局(EMA)委员会(CHMP)对Alhemo®(concizumab)给出了积极意见,推荐批准其作为12岁及以上血友病A或B型合并抑制物患者的首个每日一次皮下预防性治疗[1][2] - Alhemo®是一种抗组织因子通路抑制剂(TFPI)单克隆抗体,通过阻断TFPI蛋白来确保凝血酶的产生,从而帮助凝血并预防出血,即使其他凝血因子缺失或功能不足[2][3] - Alhemo®的上市将为血友病合并抑制物患者提供一种重要的新治疗选择,可以减轻他们的身体、情感和整体治疗负担,因为它采用便携式预混填充笔,可以在室温下存放长达4周[2] 公司概况 - 诺和诺德是一家总部位于丹麦的全球领先的医疗保健公司,成立于1923年,致力于战胜严重慢性疾病[6] - 公司在全球80个国家拥有约69,000名员工,产品销往约170个国家[6] 产品信息 - Alhemo®是一种抗TFPI单克隆抗体,通过阻断TFPI蛋白来确保凝血酶的产生,从而帮助凝血并预防出血[3] - Alhemo®已获得澳大利亚[8]和瑞士[9]批准用于12岁及以上血友病A或B型合并抑制物患者的治疗,在日本[10]获批用于12岁及以上血友病A或B型(有无抑制物)患者的常规预防性治疗 临床试验结果 - explorer7临床试验结果显示,与未接受预防性治疗的患者相比,接受Alhemo®预防性治疗的患者每年自发性和创伤性出血事件减少86%,平均年出血率从11.8降至1.7[4][12] - 接受Alhemo®预防性治疗的患者中位年出血率为0,而未接受预防性治疗的患者为9.8[12] - Alhemo®在该试验中的安全性和耐受性在预期范围内[12]

VANCOUVER, British Columbia, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Novo Resources Corp. (Novo or the Company) (ASX: NVO) (TSX: NVO) (OTCQX: NSRPF) is pleased to advise the release of its 2024 Sustainability Report, which outlines progress over the past year. The report is available on the Company’s website - Novo Sustainability Novo’s 2024 Sustainability Report demonstrates that Novo remains committed to sustainability as we execute our exploration strategy and the Company’s stakeholders, including local commu ...

Novo Nordisk (NVO) closed the most recent trading day at $117.81, moving -1.64% from the previous trading session. The stock trailed the S&P 500, which registered a daily loss of 0.76%. Elsewhere, the Dow lost 0.75%, while the tech-heavy Nasdaq lost 1.01%.The the stock of drugmaker has fallen by 12.51% in the past month, lagging the Medical sector's loss of 3.35% and the S&P 500's gain of 4.31%.Investors will be eagerly watching for the performance of Novo Nordisk in its upcoming earnings disclosure. The co ...

Novo Nordisk (NVO) ended the recent trading session at $117.20, demonstrating a -0.48% swing from the preceding day's closing price. The stock fell short of the S&P 500, which registered a gain of 0.97% for the day. At the same time, the Dow added 0.3%, and the tech-heavy Nasdaq gained 1.45%.The the stock of drugmaker has fallen by 10.72% in the past month, lagging the Medical sector's loss of 3.72% and the S&P 500's gain of 5.41%.Market participants will be closely following the financial results of Novo N ...